Erratum: Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes (PLoS ONE (2015) 10:9 (e0136851) DOI: 10.1371/journal.pone.0136851);Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  McAuliffe, Priscilla F ^a,b   Evans, Kurt W ^a   Akcakanat, Argun ^a   Chen, Ken ^a   Zheng, Xiaofeng ^a   Zhao, Hao ^a   Eterovic, Agda Karina ^a   Sangai, Takafumi ^a,c   Holder, Ashley M ^a,d   Sharma, Chandeshwar ^a,e   Chen, Huiqin ^a   Do, Kim Anh ^a   Tarco, Emily ^a   Gagea, Mihai ^a   Naff, Katherine A ^a   Sahin, Aysegul ^a   Multani, Asha S ^a   Black, Dalliah M ^a   Mittendorf, Elizabeth A ^a   Bedrosian, Isabelle ^a   Mills, Gordon B ^a   Gonzalez Angulo, Ana Maria ^a   Meric Bernstam, Funda ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c CHIBA UNIVERSITY   (Japan)

^d WASHINGTON UNIVERSITY   (United States)

^e Interim Program Director   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA; HORMONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CELL CULTURE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR INVERSION PROBE ARRAY; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PREDICTION; RECURRENCE FREE SURVIVAL; REVERSE PHASE PROTEIN ARRAY; SHORT TANDEM REPEAT; SOMATIC MUTATION; TUMOR GENE; TUMOR XENOGRAFT; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR RECURRENCE; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84943339740     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151121     Document Type: Erratum

References (51)

1. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(11):1821-8. Epub 2010/03/17. doi: JCO.2009.25.3286 [pii] doi: 10.1200/JCO.2009.25.3286 PMID: 20231683; PubMed Central PMCID: PMC2860366.
2. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460-9. Epub 1999/03/18. PMID: 10080586.
3. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-22. Epub 2007/09/06. doi: JCO.2007.10.6823 [pii] doi: 10.1200/JCO.2007.10.6823 PMID: 17785706.
4. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147 PMID: 18250347.
5. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nature reviews. 2007;7(9):659-72. Epub 2007/08/28. doi: nrc2193 [pii] doi: 10.1038/nrc2193 PMID: 17721431.
6. Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, et al. Setting up a wide panel of patientderived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer medicine. 2015;4(2):201-11. doi: 10.1002/cam4.357 PMID: 25470237; PubMed Central PMCID: PMC4329004.
7. Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader C, et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast cancer research and treatment. 2012;133(2):595-606. Epub 2011/10/18. doi: 10.1007/s10549-011-1815-5 PMID: 22002565.
8. Vick B, Schneider S, Ksienzyk B, Greif PA, Fiegl M, Subklewe M, et al. Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution. Blood. 2013;122(21):49.
9. Uronis JM, Osada T, McCall S, Yang XY, Mantyh C, Morse MA, et al. Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS ONE. 2012;7(6):e38422. Epub 2012/06/08. doi: 10.1371/journal.pone.0038422 PMID: 22675560; PubMed Central PMCID: PMC3366969.
10. Hao C, Wang L, Peng S, Cao M, Li H, Hu J, et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer letters. 2015;357(1):179-85. doi: 10.1016/j.canlet.2014.11.024 PMID: 25444907; PubMed Central PMCID: PMC4301580.
11. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular oncology. 2009;3(5-6):469-82. Epub 2009/08/29. doi: 10.1016/j.molonc.2009.07.003 PMID: 19713161.
12. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer research. 2013;73(15):4885-97. doi: 10.1158/0008-5472. CAN-12-4081 PMID: 23737486; PubMed Central PMCID: PMC3732575.
13. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nature protocols. 2007;2(2):247-50. Epub 2007/04/05. doi: nprot.2007.25 [pii] doi: 10.1038/nprot.2007.25 PMID: 17406581.
14. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989-98. Epub 2007/07/04. doi: 13/13/3989 [pii] doi: 10.1158/1078-0432. CCR-07-0078 PMID: 17606733.
15. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014;20(5):1288-97. doi: 10. 1158/1078-0432. CCR-13-2611 PMID: 24398046; PubMed Central PMCID: PMC3947430.
16. Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, et al. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. International journal of cancer. 2015;136(12):2940-8. doi: 10.1002/ijc.29344 PMID: 25404014.
17. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. Journal of the National Cancer Institute. 2009;101(1):6-8. Epub 2009/01/01. doi: djn481 [pii] doi: 10.1093/jnci/djn481 PMID: 19116380.
18. Lin MT, Tseng LH, Kamiyama H, Kamiyama M, Lim P, Hidalgo M, et al. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Bio-Techniques. 2010;48(3):211-8. Epub 2010/04/03. doi: 000113363 [pii] doi: 10.2144/000113363 PMID: 20359302; PubMed Central PMCID: PMC3065779.
19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12(15):4652-61. Epub 2006/08/11. doi: 12/15/4652 [pii] doi: 10.1158/1078-0432. CCR-06-0113 PMID: 16899615.
20. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17(9):2799-806. Epub 2011/03/11. doi: 1078-0432. CCR-10-2580 [pii] doi: 10.1158/1078-0432. CCR-10-2580 PMID: 21389100; PubMed Central PMCID: PMC3307341.
21. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011;17(17):5793-800. Epub 2011/07/12. doi: 1078-0432. CCR-11-0341 [pii] doi: 10.1158/1078-0432. CCR-11-0341 PMID: 21742805; PubMed Central PMCID: PMC3210576.
22. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular cancer therapeutics. 2011;10(8):1311-6. Epub 2011/06/16. doi: 1535-7163. MCT-11-0233 [pii] doi: 10.1158/1535-7163. MCT-11-0233 PMID: 21673092.
23. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. The American journal of pathology. 2012;180(2):599-607. doi: 10.1016/j.ajpath.2011.10.036 PMID: 22189618; PubMed Central PMCID: PMC3349876.
24. Ryba T, Battaglia D, Pope BD, Hiratani I, Gilbert DM. Genome-scale analysis of replication timing: from bench to bioinformatics. Nature protocols. 2011;6(6):870-95. Epub 2011/06/04. doi: 10.1038/nprot. 2011.328 nprot.2011.328 [pii]. PMID: 21637205; PubMed Central PMCID: PMC3111951.
25. Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, et al. Analysis of molecular inversion probe performance for allele copy number determination. Genome biology. 2007;8(11):R246. Epub 2007/11/22. doi: gb-2007-8-11-r246 [pii] doi: 10.1186/gb-2007-8-11-r246 PMID: 18028543; PubMed Central PMCID: PMC2258201.
26. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Molecular cancer therapeutics. 2011;10(6):1093-101. Epub 2011/04/15. doi: 1535-7163. MCT-10-1089 [pii] doi: 10.1158/1535-7163. MCT-10-1089 PMID: 21490305; PubMed Central PMCID: PMC3112276.
27. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, et al. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem. 2015;61(3):544-53. doi: 10.1373/clinchem.2014.231100 PMID: 25626406.
28. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surgical oncology clinics of North America. 2013;22(4):641-64. Epub 2013/09/10. doi: 10. 1016/j.soc.2013.06.008 PMID: 24012393.
29. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research. 2012;22(3):568-76. Epub 2012/02/04. doi: 10.1101/gr.129684.111 PMID: 22300766; PubMed Central PMCID: PMC3290792.
30. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014;20(14):3870-83. Epub 2014/06/05. doi: 10.1158/1078-0432. CCR-13-1507 PMID: 24895461; PubMed Central PMCID: PMC4112583.
31. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics (Oxford, England). 2003;19(10):1236-42. Epub 2003/07/02. PMID: 12835267.
32. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine. 1990;9(7):811-8. Epub 1990/07/01. PMID: 2218183.
33. Efron B, Tibshirani R. Empirical bayes methods and false discovery rates for microarrays. Genetic epidemiology. 2002;23(1):70-86. Epub 2002/07/12. doi: 10.1002/gepi.1124 PMID: 12112249.
34. Ring BZ, Chang S, Ring LW, Seitz RS, Ross DT. Gene expression patterns within cell lines are predictive of chemosensitivity. BMC genomics. 2008;9:74. Epub 2008/02/12. doi: 10.1186/1471-2164-9-74 PMID: 18261237; PubMed Central PMCID: PMC2263043.
35. Wichert S, Fokianos K, Strimmer K. Identifying periodically expressed transcripts in microarray time series data. Bioinformatics (Oxford, England). 2004;20(1):5-20. Epub 2003/12/25. PMID: 14693803.
36. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS ONE. 2011;6(8):e23543. Epub 2011/08/23. doi: 10.1371/journal.pone.0023543 PONE-D-11-02818 [pii]. PMID: 21858162; PubMed Central PMCID: PMC3155554.
37. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18(19):5314-28. Epub 2012/07/25. doi: 10.1158/1078-0432. CCR-12-0372 PMID: 22825584.
38. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute. 2008;100(9):672-9. doi: 10.1093/jnci/djn123 PMID: 18445819.
39. Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. The American journal of pathology. 1998;152(5):1299-311. Epub 1998/05/20. PMID: 9588898; PubMed Central PMCID: PMC1858587.
40. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. Journal of translational medicine. 2012;10:125. Epub 2012/06/20. doi: 10.1186/1479-5876-10-125 PMID: 22709571; PubMed Central PMCID: PMC3439334.
41. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature medicine. 2011;17(11):1514-20. Epub 2011/10/25. doi: 10.1038/nm.2454 PMID: 22019887; PubMed Central PMCID: PMC3553601.
42. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol. 2012;30(4):e45-8. Epub 2011/12/21. doi: JCO.2011.36.9678 [pii] doi: 10.1200/JCO.2011.36.9678 PMID: 22184402.
43. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013. doi: 10.1158/2159-8290. CD-14-0001 PMID: 25185190; PubMed Central PMCID: PMC4167608.
44. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999-1005. Epub 2010/04/16. doi: 10.1038/nature08989 PMID: 20393555; PubMed Central PMCID: PMC2872544.
45. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, Chung LW. Can cancer cells transform normal host cells into malignant cells? British journal of cancer. 1997;76(9):1134-8. Epub 1997/01/01. PMID: 9365160; PubMed Central PMCID: PMC2228111.
46. Pathak S, Nemeth MA, Multani AS. Human tumor xenografts in nude mice are not always of human origin: a warning signal. Cancer. 1998;83(9):1891-3. Epub 1998/11/07. doi: 10.1002/(SICI)1097-0142(19981101)83:9<1891::AID-CNCR3>3.0.CO;2-U [pii]. PMID: 9806646.
47. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008;112(11):2352-8. PMID: 18386830. doi: 10.1002/cncr.23456
48. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953-8. Epub 2009/07/15. doi: mdp263 [pii] doi: 10.1093/annonc/mdp263 PMID: 19596702; PubMed Central PMCID: PMC2791352.
49. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Perez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Molecular cancer therapeutics. 2014;13(5):1382-9. doi: 10.1158/1535-7163. MCT-13-0482 PMID: 24608573; PubMed Central PMCID: PMC4348062.
50. Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol. 2012;2012:568567. Epub 2012/05/02. doi: 10.1155/2012/568567 PMID: 22547927; PubMed Central PMCID: PMC3324927.
51. Hylander BL, Punt N, Tang H, Hillman J, Vaughan M, Bshara W, et al. Origin of the vasculature supporting growth of primary patient tumor xenografts. Journal of translational medicine. 2013;11:110. Epub 2013/05/04. doi: 10.1186/1479-5876-11-110 PMID: 23639003; PubMed Central PMCID: PMC3660244.